Global Pharmaceutical Contract Development and Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Comprehensive Study by Application (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users), Services (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services), Manufacturing type (Primary manufacturing (drug substances), Secondary manufacturing (pills, topical formulations, injectables)), Type (Supplier (original equipment manufacturer), Toller) Players and Region - Global Market Outlook to 2027

Pharmaceutical Contract Development and Manufacturing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Pharmaceutical Contract Development and Manufacturing Market Overview:
The pharmaceutical industry is having a major share in contract manufacturing. The reason is that buying equipment for the mass production of certain chemicals is very costly, and some companies can't do it. Pharmaceutical contract development and manufacturing organizations offer one-stop solutions from development to manufacturing to all the pharmaceutical and medical device companies on a contract basis. Most of the small-sized pharmaceutical and biopharmaceutical companies prefer outsourcing their development and manufacturing organization activities due to a lack of internal capabilities. In addition, favourable regulatory affairs in developing economies and assurance of quality services are other major drivers for contract development and the manufacturing organization market. Most of the pharmaceutical and biopharmaceutical companies are outsourcing their manufacturing activities to CDMOs in order to meet the rising demand for small molecules and biologics in emerging countries. This is expected to drive market growth over the estimated period.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledThermo Fisher Scientific Inc. (United States), Catalent, Inc. (United States), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (United States), Aenova Group (Germany), Consort Medical plc (United Kingdom) and Almac Group (United Kingdom)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • Increasing Investments in Pharmaceutical R&D
  • Growing Demand for Generics
  • The increasing number of small and medium-sized pharmaceutical companies

Roadblocks
  • Lack of Control over that product

Opportunities
  • Asia-Pacific is expected to witness the highest growth in the CRO market, owing to the low cost offered by the region, as compared to the United States and other developed economies
  • The growing outsourcing trend by small and large pharmaceutical companies represents a promising opportunity for Contract Development and Manufacturing Organizations As pharma shifts its focus to more research and development and less in-house manufacturing,

Challenges
  • Capacity Constraints and Loss of Flexibility and Responsiveness


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Thermo Fisher Scientific Inc. (United States), Catalent, Inc. (United States), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (United States), Aenova Group (Germany), Consort Medical plc (United Kingdom) and Almac Group (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany) and Evonik Industries AG (Germany). Analyst at AMA Research see Germany Players to retain maximum share of Global Pharmaceutical Contract Development and Manufacturing market by 2027. Considering Market by Services, the sub-segment i.e. Pharmaceutical Manufacturing Services will boost the Pharmaceutical Contract Development and Manufacturing market. Considering Market by Manufacturing type, the sub-segment i.e. Primary manufacturing (drug substances) will boost the Pharmaceutical Contract Development and Manufacturing market. Considering Market by Type , the sub-segment i.e. Supplier (original equipment manufacturer) will boost the Pharmaceutical Contract Development and Manufacturing market.

In October 2019 ANI launches the CDMO arm after WellSpring integration, the launch of the brand demonstrates the progress that the company has made since the WellSpring acquisition. The newly-established business was presented at the CPhI Worldwide event in Frankfurt, Germany.

What Can be Explored with the Pharmaceutical Contract Development and Manufacturing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Pharmaceutical Contract Development and Manufacturing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Pharmaceutical Contract Development and Manufacturing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Pharmaceutical Contract Development and Manufacturing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Pharmaceutical Contract Development and Manufacturing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Pharmaceutical Contract Development and Manufacturing Providers, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Big Pharma
  • Small & Mid-size Pharma
  • Generic Pharmaceutical Companies
  • Other End Users
By Services
  • Pharmaceutical Manufacturing Services
  • Biologics Manufacturing Services
  • Drug Development Services

By Manufacturing type
  • Primary manufacturing (drug substances)
  • Secondary manufacturing (pills, topical formulations, injectables)

By Type
  • Supplier (original equipment manufacturer)
  • Toller

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Investments in Pharmaceutical R&D
      • 3.2.2. Growing Demand for Generics
      • 3.2.3. The increasing number of small and medium-sized pharmaceutical companies
    • 3.3. Market Challenges
      • 3.3.1. Capacity Constraints and Loss of Flexibility and Responsiveness
    • 3.4. Market Trends
      • 3.4.1. The increasing outsourcing in the pharmaceuticals industry
      • 3.4.2. The strong merger and acquisition activities in the CDMO
      • 3.4.3. Increasing Cdmo Manufacturing Footprint in Asian Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmaceutical Contract Development and Manufacturing, by Application, Services, Manufacturing type, Type and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pharmaceutical Contract Development and Manufacturing (Value)
      • 5.2.1. Global Pharmaceutical Contract Development and Manufacturing by: Application (Value)
        • 5.2.1.1. Big Pharma
        • 5.2.1.2. Small & Mid-size Pharma
        • 5.2.1.3. Generic Pharmaceutical Companies
        • 5.2.1.4. Other End Users
      • 5.2.2. Global Pharmaceutical Contract Development and Manufacturing by: Services (Value)
        • 5.2.2.1. Pharmaceutical Manufacturing Services
        • 5.2.2.2. Biologics Manufacturing Services
        • 5.2.2.3. Drug Development Services
      • 5.2.3. Global Pharmaceutical Contract Development and Manufacturing by: Manufacturing type (Value)
        • 5.2.3.1. Primary manufacturing (drug substances)
        • 5.2.3.2. Secondary manufacturing (pills, topical formulations, injectables)
      • 5.2.4. Global Pharmaceutical Contract Development and Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pharmaceutical Contract Development and Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Catalent, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza Group Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Recipharm AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vetter Pharma International GMBH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. FAMAR Health Care Services (Greece)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aenova Group (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Consort Medical plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Almac Group (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pharmaceutical Contract Development and Manufacturing Sale, by Application, Services, Manufacturing type, Type and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pharmaceutical Contract Development and Manufacturing (Value)
      • 7.2.1. Global Pharmaceutical Contract Development and Manufacturing by: Application (Value)
        • 7.2.1.1. Big Pharma
        • 7.2.1.2. Small & Mid-size Pharma
        • 7.2.1.3. Generic Pharmaceutical Companies
        • 7.2.1.4. Other End Users
      • 7.2.2. Global Pharmaceutical Contract Development and Manufacturing by: Services (Value)
        • 7.2.2.1. Pharmaceutical Manufacturing Services
        • 7.2.2.2. Biologics Manufacturing Services
        • 7.2.2.3. Drug Development Services
      • 7.2.3. Global Pharmaceutical Contract Development and Manufacturing by: Manufacturing type (Value)
        • 7.2.3.1. Primary manufacturing (drug substances)
        • 7.2.3.2. Secondary manufacturing (pills, topical formulations, injectables)
      • 7.2.4. Global Pharmaceutical Contract Development and Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmaceutical Contract Development and Manufacturing: by Application(USD Million)
  • Table 2. Pharmaceutical Contract Development and Manufacturing Big Pharma , by Region USD Million (2016-2021)
  • Table 3. Pharmaceutical Contract Development and Manufacturing Small & Mid-size Pharma , by Region USD Million (2016-2021)
  • Table 4. Pharmaceutical Contract Development and Manufacturing Generic Pharmaceutical Companies , by Region USD Million (2016-2021)
  • Table 5. Pharmaceutical Contract Development and Manufacturing Other End Users , by Region USD Million (2016-2021)
  • Table 6. Pharmaceutical Contract Development and Manufacturing: by Services(USD Million)
  • Table 7. Pharmaceutical Contract Development and Manufacturing Pharmaceutical Manufacturing Services , by Region USD Million (2016-2021)
  • Table 8. Pharmaceutical Contract Development and Manufacturing Biologics Manufacturing Services , by Region USD Million (2016-2021)
  • Table 9. Pharmaceutical Contract Development and Manufacturing Drug Development Services , by Region USD Million (2016-2021)
  • Table 10. Pharmaceutical Contract Development and Manufacturing: by Manufacturing type(USD Million)
  • Table 11. Pharmaceutical Contract Development and Manufacturing Primary manufacturing (drug substances) , by Region USD Million (2016-2021)
  • Table 12. Pharmaceutical Contract Development and Manufacturing Secondary manufacturing (pills, topical formulations, injectables) , by Region USD Million (2016-2021)
  • Table 13. South America Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2016-2021)
  • Table 14. South America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 15. South America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 16. South America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 17. South America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 18. Brazil Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 19. Brazil Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 20. Brazil Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 21. Brazil Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 22. Argentina Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 23. Argentina Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 24. Argentina Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 25. Argentina Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 27. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 28. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 29. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2016-2021)
  • Table 31. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 33. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 34. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 35. China Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 36. China Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 37. China Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 38. China Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 39. Japan Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 40. Japan Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 41. Japan Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 42. Japan Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 43. India Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 44. India Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 45. India Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 46. India Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 47. South Korea Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 48. South Korea Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 49. South Korea Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 50. South Korea Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 51. Taiwan Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 52. Taiwan Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 53. Taiwan Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 54. Taiwan Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 55. Australia Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 56. Australia Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 57. Australia Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 58. Australia Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 63. Europe Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2016-2021)
  • Table 64. Europe Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 65. Europe Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 66. Europe Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 67. Europe Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 68. Germany Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 69. Germany Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 70. Germany Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 71. Germany Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 72. France Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 73. France Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 74. France Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 75. France Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 76. Italy Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 77. Italy Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 78. Italy Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 79. Italy Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 80. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 81. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 82. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 83. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 84. Netherlands Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 85. Netherlands Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 86. Netherlands Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 87. Netherlands Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 88. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 89. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 90. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 91. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 92. MEA Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2016-2021)
  • Table 93. MEA Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 94. MEA Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 95. MEA Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 96. MEA Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 97. Middle East Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 98. Middle East Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 99. Middle East Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 100. Middle East Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 101. Africa Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 102. Africa Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 103. Africa Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 104. Africa Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 105. North America Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2016-2021)
  • Table 106. North America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 107. North America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 108. North America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 109. North America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 110. United States Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 111. United States Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 112. United States Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 113. United States Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 114. Canada Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 115. Canada Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 116. Canada Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 117. Canada Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 118. Mexico Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2016-2021)
  • Table 119. Mexico Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2016-2021)
  • Table 120. Mexico Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2016-2021)
  • Table 121. Mexico Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2016-2021)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Pharmaceutical Contract Development and Manufacturing: by Application(USD Million)
  • Table 133. Pharmaceutical Contract Development and Manufacturing Big Pharma , by Region USD Million (2022-2027)
  • Table 134. Pharmaceutical Contract Development and Manufacturing Small & Mid-size Pharma , by Region USD Million (2022-2027)
  • Table 135. Pharmaceutical Contract Development and Manufacturing Generic Pharmaceutical Companies , by Region USD Million (2022-2027)
  • Table 136. Pharmaceutical Contract Development and Manufacturing Other End Users , by Region USD Million (2022-2027)
  • Table 137. Pharmaceutical Contract Development and Manufacturing: by Services(USD Million)
  • Table 138. Pharmaceutical Contract Development and Manufacturing Pharmaceutical Manufacturing Services , by Region USD Million (2022-2027)
  • Table 139. Pharmaceutical Contract Development and Manufacturing Biologics Manufacturing Services , by Region USD Million (2022-2027)
  • Table 140. Pharmaceutical Contract Development and Manufacturing Drug Development Services , by Region USD Million (2022-2027)
  • Table 141. Pharmaceutical Contract Development and Manufacturing: by Manufacturing type(USD Million)
  • Table 142. Pharmaceutical Contract Development and Manufacturing Primary manufacturing (drug substances) , by Region USD Million (2022-2027)
  • Table 143. Pharmaceutical Contract Development and Manufacturing Secondary manufacturing (pills, topical formulations, injectables) , by Region USD Million (2022-2027)
  • Table 144. South America Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2022-2027)
  • Table 145. South America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 146. South America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 147. South America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 148. South America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 149. Brazil Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 150. Brazil Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 151. Brazil Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 152. Brazil Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 153. Argentina Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 154. Argentina Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 155. Argentina Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 156. Argentina Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 157. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 158. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 159. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 160. Rest of South America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 161. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2022-2027)
  • Table 162. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 163. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 164. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 165. Asia Pacific Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 166. China Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 167. China Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 168. China Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 169. China Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 170. Japan Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 171. Japan Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 172. Japan Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 173. Japan Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 174. India Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 175. India Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 176. India Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 177. India Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 178. South Korea Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 179. South Korea Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 180. South Korea Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 181. South Korea Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 182. Taiwan Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 183. Taiwan Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 184. Taiwan Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 185. Taiwan Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 186. Australia Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 187. Australia Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 188. Australia Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 189. Australia Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 191. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 192. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 193. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 194. Europe Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2022-2027)
  • Table 195. Europe Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 196. Europe Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 197. Europe Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 198. Europe Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 199. Germany Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 200. Germany Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 201. Germany Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 202. Germany Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 203. France Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 204. France Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 205. France Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 206. France Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 207. Italy Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 208. Italy Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 209. Italy Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 210. Italy Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 211. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 212. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 213. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 214. United Kingdom Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 215. Netherlands Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 216. Netherlands Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 217. Netherlands Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 218. Netherlands Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 219. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 220. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 221. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 222. Rest of Europe Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 223. MEA Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2022-2027)
  • Table 224. MEA Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 225. MEA Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 226. MEA Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 227. MEA Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 228. Middle East Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 229. Middle East Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 230. Middle East Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 231. Middle East Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 232. Africa Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 233. Africa Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 234. Africa Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 235. Africa Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 236. North America Pharmaceutical Contract Development and Manufacturing, by Country USD Million (2022-2027)
  • Table 237. North America Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 238. North America Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 239. North America Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 240. North America Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 241. United States Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 242. United States Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 243. United States Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 244. United States Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 245. Canada Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 246. Canada Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 247. Canada Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 248. Canada Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 249. Mexico Pharmaceutical Contract Development and Manufacturing, by Application USD Million (2022-2027)
  • Table 250. Mexico Pharmaceutical Contract Development and Manufacturing, by Services USD Million (2022-2027)
  • Table 251. Mexico Pharmaceutical Contract Development and Manufacturing, by Manufacturing type USD Million (2022-2027)
  • Table 252. Mexico Pharmaceutical Contract Development and Manufacturing, by Type USD Million (2022-2027)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmaceutical Contract Development and Manufacturing: by Application USD Million (2016-2021)
  • Figure 5. Global Pharmaceutical Contract Development and Manufacturing: by Services USD Million (2016-2021)
  • Figure 6. Global Pharmaceutical Contract Development and Manufacturing: by Manufacturing type USD Million (2016-2021)
  • Figure 7. South America Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 9. Europe Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 10. MEA Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 11. North America Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 12. Global Pharmaceutical Contract Development and Manufacturing share by Players 2021 (%)
  • Figure 13. Global Pharmaceutical Contract Development and Manufacturing share by Players (Top 3) 2021(%)
  • Figure 14. Global Pharmaceutical Contract Development and Manufacturing share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2021
  • Figure 18. Catalent, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Catalent, Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Lonza Group Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza Group Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 22. Recipharm AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 23. Recipharm AB (Sweden) Revenue: by Geography 2021
  • Figure 24. Vetter Pharma International GMBH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Vetter Pharma International GMBH (Germany) Revenue: by Geography 2021
  • Figure 26. FAMAR Health Care Services (Greece) Revenue, Net Income and Gross profit
  • Figure 27. FAMAR Health Care Services (Greece) Revenue: by Geography 2021
  • Figure 28. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. AbbVie Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Aenova Group (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Aenova Group (Germany) Revenue: by Geography 2021
  • Figure 32. Consort Medical plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Consort Medical plc (United Kingdom) Revenue: by Geography 2021
  • Figure 34. Almac Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Almac Group (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Global Pharmaceutical Contract Development and Manufacturing: by Application USD Million (2022-2027)
  • Figure 37. Global Pharmaceutical Contract Development and Manufacturing: by Services USD Million (2022-2027)
  • Figure 38. Global Pharmaceutical Contract Development and Manufacturing: by Manufacturing type USD Million (2022-2027)
  • Figure 39. South America Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 40. Asia Pacific Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 41. Europe Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 42. MEA Pharmaceutical Contract Development and Manufacturing Share (%), by Country
  • Figure 43. North America Pharmaceutical Contract Development and Manufacturing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific Inc. (United States)
  • Catalent, Inc. (United States)
  • Lonza Group Ltd (Switzerland)
  • Recipharm AB (Sweden)
  • Vetter Pharma International GMBH (Germany)
  • FAMAR Health Care Services (Greece)
  • AbbVie Inc. (United States)
  • Aenova Group (Germany)
  • Consort Medical plc (United Kingdom)
  • Almac Group (United Kingdom)
Additional players considered in the study are as follows:
Siegfried Holding AG (Switzerland) , Boehringer Ingelheim International GmbH (Germany) , Evonik Industries AG (Germany)
Select User Access Type

Key Highlights of Report


May 2022 203 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmaceutical Contract Development and Manufacturing Market Quantitative research analysis
Global Pharmaceutical Contract Development and Manufacturing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Pharmaceutical Contract Development and Manufacturing market are Thermo Fisher Scientific Inc. (United States), Catalent, Inc. (United States), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (United States), Aenova Group (Germany), Consort Medical plc (United Kingdom) and Almac Group (United Kingdom), to name a few.
"The increasing outsourcing in the pharmaceuticals industry " is seen as one of major influencing trends for Pharmaceutical Contract Development and Manufacturing Market during projected period 2021-2027.

Know More About Global Pharmaceutical Contract Development and Manufacturing Market Report?

Have a Query? Click Here

Other Related Reports

Tablet Coatings Comprehensive Study by Type (Sugar Coating, Sealing, Sub Coating, Syrup Coating, Colouring, Polishing), Application (Nutraceuticals, Pharmaceuticals), Polymers (Cellulosic, Vinyl, Acr...
$ 3500
Ganirelix Comprehensive Study by Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment, Premature Ovarian Failure (POF)), Form (Injection, Solution), Packaging (Single syringe, Box ...
$ 3650
Carisoprodol Tablets Comprehensive Study by Type (Carisoprodol 250 mg Tablet, Carisoprodol 350 mg Tablet), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Ph...
$ 3350
Disclosing Tablets Comprehensive Study by Composition (Erythrosine, Fluorescein, Iodine), Ager group (Children, Adults, Geriatric Population), Distribution Channel (Online, Medical Stores, Pharmacies...
$ 3450
Bromperidol Comprehensive Study by Application (Dementia, Depression, Schizophrenia, Anxiety Disorders, Psychosomatic Disorders, Others), Size (100mg, 200mg, 500mg, Others), Dosage Form (Tablet, Inj...
$ 3350
Mebeverine Comprehensive Study by Type (Tablets, Capsules, Liquid), Application (Abdominal Pain and Cramps, Constipation, Diarrhea, Flatulence), Distribution Channel (Hospital Pharmacies, Retail Phar...
$ 3450